Karamjeet Sandhu

发表

Reduced-intensity hematopoietic cell transplantation in older patients with AML/MDS: umbilical cord blood is a feasible option for patients without HLA-matched sibling donors

J. Wagner, D. Weisdorf, N. Majhail, 2012, Bone Marrow Transplantation.

Venetoclax and hypomethylating agents yield high response rates and favourable transplant outcomes in patients with newly diagnosed acute myeloid leukaemia

G. Marcucci, I. Aldoss, S. Forman, 2021, British journal of haematology.

Outcome of secondary acute myeloid leukemia treated with hypomethylating agent plus venetoclax (HMA‐Ven) or liposomal daunorubicin‐cytarabine (CPX‐351)

G. Marcucci, I. Aldoss, S. Forman, 2021, American journal of hematology.

Allogeneic Hematopoietic Cell Transplantation Outcomes in Patients Carrying Isocitrate Dehydrogenase Mutations.

D. Weisenburger, G. Marcucci, I. Aldoss, 2019, Clinical lymphoma, myeloma & leukemia.

Pulmonary hypertension is associated with increased nonrelapse mortality after allogeneic hematopoietic cell transplantation for myelofibrosis

G. Marcucci, I. Aldoss, S. Forman, 2019, Bone Marrow Transplantation.

Long-Term Outcomes of Allogeneic Hematopoietic Cell Transplant with Fludarabine and Melphalan Conditioning and Tacrolimus/Sirolimus as Graft-versus-Host Disease Prophylaxis in Patients with Acute Lymphoblastic Leukemia

I. Aldoss, S. Forman, D. Snyder, 2022 .

Melphalan-Based Reduced-Intensity Conditioning is Associated with Favorable Disease Control and Acceptable Toxicities in Patients Older Than 70 with Hematologic Malignancies Undergoing Allogeneic Hematopoietic Stem Cell Transplantation.

A. Nademanee, G. Marcucci, S. Forman, 2018, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Invasive fungal infections in acute myeloid leukemia treated with venetoclax and hypomethylating agents.

G. Marcucci, I. Aldoss, S. Forman, 2019, Blood advances.

A phase 2 study of Interleukin-22 and systemic corticosteroids as initial treatment for acute GVHD of the lower GI tract.

M. Perales, M. V. D. van den Brink, S. Devlin, 2022, Blood.

Multicenter Pilot Clinical Trial of Enasidenib As Maintenance Therapy after Allogeneic Hematopoietic Cell Transplantation in Patients with Acute Myeloid Leukemia (AML) Carrying IDH2 Mutations

G. Marcucci, I. Aldoss, S. Forman, 2022, Blood.

Long term outcomes of patients with Acute Myeloid Leukemia treated with myeloablative FTBI based conditioning with Tacrolimus and sirolimus based GVHD prophylaxis regimen: 6 year follow up from Single Center.

G. Marcucci, I. Aldoss, S. Forman, 2020, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Outcomes of Allogeneic Hematopoietic Cell Transplantation after Salvage-Therapy with Blinatumomab in Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia.

G. Marcucci, I. Aldoss, S. Forman, 2020, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Outcomes of allogeneic hematopoietic cell transplantation in adults with fusions associated with Ph-like ALL

G. Marcucci, I. Aldoss, P. Curtin, 2022, Blood advances.

Allogeneic Hematopoietic Cell Transplantation for Adult T Cell Acute Lymphoblastic Leukemia.

C. Flowers, M. Perales, A. Viswabandya, 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Total marrow and lymphoid irradiation as conditioning in haploidentical transplant with posttransplant cyclophosphamide

J. Wong, G. Marcucci, I. Aldoss, 2022, Blood advances.

Biomarker-guided preemption of steroid-refractory graft-versus-host disease with α-1-antitrypsin.

E. Holler, Yi-Bin Chen, Z. DeFilipp, 2020, Blood advances.

The MAGIC algorithm probability is a validated response biomarker of treatment of acute graft-versus-host disease.

S. Grupp, Z. DeFilipp, K. Sigel, 2019, Blood advances.

Efficacy of the combination of venetoclax and hypomethylating agents in relapsed/refractory acute myeloid leukemia

G. Marcucci, I. Aldoss, S. Forman, 2018, Haematologica.

Outcomes of Patients with Recurrent and Refractory Lymphoma Undergoing Allogeneic Hematopoietic Cell Transplantation with BEAM Conditioning and Sirolimus- and Tacrolimus-Based GVHD Prophylaxis.

A. Nademanee, S. Forman, A. Salhotra, 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

A critical review of belumosudil in adult and pediatric patients with chronic graft-versus-host disease

A. Salhotra, B. Modi, R. Nakamura, 2022, Expert review of clinical immunology.

J. Wagner, T. Singleton, D. Weisdorf, 2012, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

J. Wagner, T. Singleton, D. Weisdorf, 2013 .

Long-term Outcomes of Allogeneic Hematopoietic Cell transplantation with Fludarabine and Melphalan Conditioning and Tacrolimus/Sirolimus as GVHD prophylaxis in Patients with Acute Lymphoblastic Leukemia.

G. Marcucci, I. Aldoss, S. Forman, 2020, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Elevated Eosinophil Count Following Pembrolizumab Treatment for Non-Small Cell Lung Cancer

R. Salgia, Isa Mambetsariev, Jeremy Fricke, 2021, Cureus.

Extramedullary disease relapse and progression after blinatumomab therapy for treatment of acute lymphoblastic leukemia

G. Marcucci, I. Aldoss, P. Curtin, 2021, Cancer.

Allogeneic Hematopoietic Cell Transplantation for Relapsed and Refractory Philadelphia Negative B Cell ALL in the Era of Novel Salvage Therapies.

G. Marcucci, I. Aldoss, S. Forman, 2021, Transplantation and cellular therapy.

Safety and efficacy of obecabtagene autoleucel (obe-cel, AUTO1), a fast-off rate CD19 CAR, in relapsed/refractory adult B-cell acute lymphoblastic leukemia (r/r B-ALL): Top line results of the pivotal FELIX study.

A. Logan, E. Tholouli, W. Brugger, 2023, Journal of Clinical Oncology.

Outcome of allogeneic hematopoietic cell transplantation after venetoclax and hypomethylating agent therapy for acute myeloid leukemia.

G. Marcucci, I. Aldoss, S. Forman, 2020, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Tacrolimus initial steady state level in post-transplant cyclophosphamide based GvHD prophylaxis regimens

G. Marcucci, I. Aldoss, S. Forman, 2021, Bone Marrow Transplantation.

A review of low dose interleukin-2 therapy in management of chronic graft-versus-host-disease

A. Salhotra, B. Modi, R. Nakamura, 2023, Expert review of clinical immunology.

Post-transplant sinusoidal obstruction syndrome in adult patients with B-cell Acute Lymphoblastic Leukemia treated with pre-transplant Inotuzumab.

G. Marcucci, I. Aldoss, P. Curtin, 2023, Transplantation and cellular therapy.

Association of leukemia genetics with response to venetoclax and hypomethylating agents in relapsed/refractory acute myeloid leukemia

G. Marcucci, I. Aldoss, S. Forman, 2019, American journal of hematology.